Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
BioVie presents Phase 3 study of Alzheimer's treatment at San Diego medical conference
09:11am, Monday, 26'th Jun 2023
BioVie Inc (NASDAQ:BIVI) announced that baseline data from a multicenter, randomized, placebo-controlled Phase 3 study of its Alzheimer's Disease treatment was presented at the 83rd Scientific Session
BioVie: Not Investible For Its Alzheimer's Program
04:49pm, Friday, 23'rd Jun 2023
BioVie will produce some lateral data from its phase 3 trial tomorrow. I was not overly impressed by its Alzheimer's program; the ascites program seemed more promising. The company is precariously low
BioVie set to join Russell 2000 and Russell 3000 indexes
08:26am, Friday, 23'rd Jun 2023
BioVie Inc (NASDAQ:BIVI) has announced that it will be added as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the US market opens on June 26, as part of the 2023
BioVie to present Phase 3 study data at American Diabetes Association conference
09:17am, Wednesday, 21'st Jun 2023
BioVie Inc (NASDAQ:BIVI) said it will present an abstract showcasing baseline data from its Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer's disease at the 83rd Sci
BioVie presents rationale for NE3107 trial in Parkinson's Disease treatment at IAPRD in Chicago
04:42pm, Tuesday, 16'th May 2023
BioVie Inc (NASDAQ:BIVI) has announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison's Disease was presented
BioVie aims to treat Parkinson's and Alzheimer's by focusing on inflammation
08:01am, Tuesday, 16'th May 2023
By targeting inflammation as a novel pathway, clinical-stage biotechnology company BioVie Inc (NASDAQ:BIVI) aims to discover treatments for neurological and neurodegenerative disorders and advanced li
BioVie's degenerative dementia drug candidate to be presented at psychiatry conference
10:24am, Thursday, 20'th Apr 2023
BioVie Inc (NASDAQ:BIVI) announced Thursday that a data abstract from its Phase 2 open-label trial of its degenerative dementia drug candidate has been accepted for presentation at the 78th Annual Sci
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
08:30am, Thursday, 20'th Apr 2023
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of
BioVie to present Phase 2 trial data abstracts at 2023 American Academy of Neurology Annual Meeting
12:01pm, Monday, 17'th Apr 2023
BioVie announced that data abstracts from its Phase 2 trials evaluating NE3107 in degenerative dementias and Parkinson's disease will be presented at the 2023 American Academy of Neurology Annual Meet
BioVie: Update On Alzheimer's And Parkinson's Programs, And Focus On Its Treatment For Refractory Ascites
01:06am, Wednesday, 15'th Mar 2023
BioVie's stock has moved up considerably over the past 9 months in light of promising Alzheimer's data. BioVie Day and full Phase 2 Parkinson's trial results are scheduled for this month.
BioVie Inc (NASDAQ:BIVI) revealed that it had paused patient enrollment in its Phase 2b clinical trial evaluating BIV201 for the treatment of refractory ascites after seeing encouraging data from the
Why Shares of BioVie Jumped This Week
11:04am, Friday, 10'th Mar 2023
BioVie doesn't have any marketed therapies yet. The company lost $15.6 million in the fourth quarter.
BioVie's drug NE3107 shown to help patients with muscle control in Parkinson's disease Phase 2 trial
09:36am, Monday, 06'th Mar 2023
BioVie Inc (NASDAQ:BIVI) has announced additional preliminary findings from the Parkinson's disease Phase 2 trial of its drug NE3107, showing a significant improvement over the current standard of ca
Why Shares of BioVie Jumped 51.7% in February
02:03pm, Thursday, 02'nd Mar 2023
The company is forging ahead with a phase 3 trial for its lead therapy.
BioVie announces completion of patient enrollment in Phase 3 trial assessing NE3107 in Alzheimer's
09:32am, Thursday, 02'nd Mar 2023
BioVie Inc (NASDAQ:BIVI) said its NM101 trial evaluating NE3107 in the treatment of patients with Alzheimer's Disease has achieved its revised enrollment target of 400 patients, with top-line results
